An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves open access: FL118 antitumor efficacy and therapeutic index (TI) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, April 02, 2013

An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves open access: FL118 antitumor efficacy and therapeutic index (TI)



pdf
Blogger

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments ( Atom )